VALEO PHARMA INC - VPHIF STOCK NEWS

Valeo Pharma projects record revenues for Q2 2021, attributed to the national launch of Redesca®. Anticipating a more than 40% revenue increase compared to the prior quarter, the company expects gross margins to more than double from Q1 2021. The successful uptake of Redesca® will be complemented by launches of Enerzair® Breezhaler® and Atectura® Breezhaler® in June 2021. Operational milestones include advanced recruitment for a new Respiratory sales force and rapid progress in product reimbursement negotiations.

Valeo Pharma has secured a Product Listing Agreement for its low molecular weight heparin biosimilars, Redesca and Redesca HP, to be included in the Ontario Drug Benefit Formulary starting April 30, 2021. Given that Ontario accounts for 37% of Canada's LMWH market, this listing is a significant milestone for Valeo's commercialization efforts. The President of Valeo highlighted that this move will not only provide savings for the Ontario government but also improve access for millions of Canadians reliant on public insurance for their medications. Further provincial coverage is anticipated.

Valeo Pharma has successfully upsized and closed a non-brokered private placement, raising $6.645 million through the issuance of unsecured non-convertible debenture units. Each unit comprises a debenture of $1,000 and warrants for Class 'A' shares at an exercise price of $1.60. Notably, insiders contributed $2.6 million, showcasing significant confidence in the company. Proceeds from this offering will support working capital and corporate objectives, with the debentures maturing in nine months at an interest rate of 8%.

Valeo Pharma has commenced commercial shipments of Redesca™ and Redesca HP™, its low molecular weight heparin biosimilars, across Canada. The company aims to enhance public and private reimbursement coverage while ensuring national sales coverage through dedicated key account managers. Redesca™ is positioned to be a significant contributor to Valeo's second-quarter revenues and is noted for its safety profile and cost-effectiveness for healthcare systems. The product is now available in retail pharmacies and hospitals, supporting treatment for conditions like deep vein thrombosis and COVID-19.

Valeo Pharma Inc (CSE: VPH; OTCQB: VPHIF) has finalized a letter of intent with the pan-Canadian Pharmaceutical Alliance (pCPA) for its biosimilar products, Redesca and Redesca HP. This agreement marks a significant step in the commercialization of these low molecular weight heparins for treating thromboembolic disorders, particularly during the ongoing pandemic. Valeo aims to ensure coverage under publicly funded drug plans in Canada, enhancing access to these critical treatments for patients.

Valeo Pharma Inc. has signed a commercialization agreement with Novartis for the Canadian launch of two asthma treatments, Enerzair® Breezhaler® and Atectura® Breezhaler®, slated for an initial 8-year term. With nearly 4 million Canadians suffering from asthma and the market exceeding $700M annually, this partnership positions Valeo as a key player in the respiratory sector. The products are supported by extensive clinical trials, boasting proven efficacy in improving asthma management.

Valeo Pharma Inc has partnered with the Montreal Heart Institute to conduct a clinical trial on Hesperco™, which contains 500mg of hesperidin, targeting COVID-19 patients. The study will involve 216 symptomatic patients and evaluate hesperidin's potential to decrease the severity of COVID-19 symptoms and reduce hospitalization. Hesperidin has demonstrated efficacy against SARS-CoV-2 by inhibiting key proteins necessary for the virus's entry into cells. The capsules are available for purchase online and will soon be in major health retailers.

Valeo Pharma Inc (CSE:VPH, OTCQB:VPHIF) announced that online orders for its flavonoid formulation, Hesperco™, have commenced shipping. Hesperco™ is designed to support the immune system and contains powerful antioxidants. The official retail launch is expected in early November 2020. Valeo entered into a collaboration and licensing agreement with Ingenew Pharma Inc. in April 2020 to aid in the development and commercialization of Hesperco™. With a focus on innovative prescription and OTC products, Valeo is positioned to expand its market presence.

Valeo Pharma Inc (CSE: VPH) (OTCQB: VPHIF) has commenced trading on the OTCQB market in the U.S. as of September 23, 2020. This strategic move aims to expand its shareholder base by attracting U.S. institutional and retail investors, thereby enhancing liquidity for existing shareholders. Valeo continues to maintain its listing on the CSE under the symbol 'VPH'. This milestone aligns with the company's initiatives to launch new products and pursue growth opportunities in the pharmaceutical market, focusing on Neurodegenerative Diseases, Oncology, and Hospital Specialty Products.